Pfizer (PFE) Stock Sinks As Market Gains: Here's Why

Zacks
Zacks에서 열기
Pfizer (PFE) Stock Sinks As Market Gains: Here's Why

Pfizer (PFE) ended the recent trading session at $29.45, demonstrating a -1.17% change from the preceding day's closing price. This move lagged the S&P 500's daily gain of 0.28%. Meanwhile, the Dow gained 0.19%, and the Nasdaq, a tech-heavy index, added 0.27%.

Prior to today's trading, shares of the drugmaker had gained 3.76% outpaced the Medical sector's gain of 2.43% and the S&P 500's loss of 0.2%.

Market participants will be closely following the financial results of Pfizer in its upcoming release. The company plans to announce its earnings on November 3, 2026. The company is predicted to post an EPS of $0.72, indicating a 17.24% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $16.13 billion, down 3.14% from the year-ago period.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $2.94 per share and a revenue of $62.48 billion, representing changes of -8.7% and -0.15%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Pfizer. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 1.05% decrease. At present, Pfizer boasts a Zacks Rank of #3 (Hold).

Valuation is also important, so investors should note that Pfizer has a Forward P/E ratio of 10.12 right now. This valuation marks a discount compared to its industry average Forward P/E of 17.54.

It's also important to note that PFE currently trades at a PEG ratio of 2.02. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 2.02.

The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 218, placing it within the bottom 12% of over 250 industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Pfizer Inc. (PFE): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research